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Introduction
Bronchiolitis is a common viral lower respiratory tract infection in infants characterized by acute small airway inflammation, and represents the leading cause for hospital admission during the first year of life [1] . In high income countries, approximately one out of eight infants hospitalized with bronchiolitis require admission to Intensive Care Units (ICU) for respiratory support as a result of progressive respiratory distress with respiratory failure and hypoxemia [2, 3] . Despite a general trend towards a reduction in hospital admissions overall, bronchiolitisrelated hospitalization costs have recently increased amounting to US$1.73 billion per year in the US [4] . In the past decades, pharmacological interventions have failed to show any benefit, and as a result, consensus guidelines emphasize supportive treatment options [2, 3, [5] [6] [7] [8] . While invasive ventilation (IV) was traditionally considered the cornerstone of treatment for severe bronchiolitis in ICU, over recent years, an increasing number of single center studies have reported benefits associated with early use of non-invasive ventilation (NIV) and High-Flow Nasal Cannula (HFNC) therapy to reduce the need for intubation and IV in bronchiolitis [9] [10] [11] [12] [13] .
The aims of this study were to describe the population-based admission rate and severity of bronchiolitis in infants in Australia and New Zealand admitted to intensive care, to determine risk factors for invasive ventilation, and to assess trends in admission rate, management, outcome and associated direct health care costs over a 13 year period from 2002-2014. December 2014 were included. Elective admissions were excluded and infants with preexisting tracheostomies were excluded.
Outcomes and definitions:
The primary outcome was defined as the proportion of infants requiring intubation and invasive ventilation (IV). Non-invasive ventilation (NIV) was defined as continous positive airway pressure (CPAP) with or without pressure support delivered through a nasal mask, full-face mask, or a nasopharyngeal tube. Mechanical ventilation was defined as either IV and/or NIV.
Since 2010, the ANZPIC registry has been prospectively recording the use of highflow nasal cannulae oxygen (HFNC) therapy. HFNC was defined as > 1L/kg/min flow of a gas oxygen mixture through nasal cannula, and was coded separately from mechanical ventilation support [12, 13] . Data analyses were therefore separated into two periods: a period before widespread use of HFNC therapy (2002) (2003) (2004) (2005) (2006) (2007) (2008) (2009) ) and a period post widespread introduction of HFNC therapy (2010) (2011) (2012) (2013) (2014) . With the exception of one PICU, HFNC was not routinely used in the main PICUs and ICUs prior to 2010.
Cost estimates methodology are provided in the Supplementary Material.
Statistics:
Data are presented as percentages and numbers or means with standard deviation.
T-tests were used to compare subgroups. Population-based admission rate estimates were calculated. We assessed linear trends in respiratory support over the 13-year period. In addition, trends during the 13-year study period were assessed by comparing risk-adjusted need for invasive ventilation. We constructed a multivariate prediction model for the need for invasive ventilation. For multivariable models, all significant predictors from the univariable analyses were used. We used a backward stepwise elimination procedure to eliminate non-significant predictors based on p>0.05.
All PICUs in Australia and New Zealand contributed to the ANZPIC registry for the entire duration of the study period. The number of general ICUs contributing to the registry increased from 6 to 19 during the study period. In order to account for potential reporting bias, the following predefined subgroup analyses were performed: i) specialized pediatric ICUs (PICUs); ii) general (mixed adult and pediatric) ICUs; iii) pediatric and general ICUs that had been contributing for the entire length of the study period to the ANZPIC registry.
Further details of risk prediction models are provided in the Supplementary Material.
All analyses were conducted using Stata (version 12.1, Stata Corp, College Station, Texas, USA). P-values less than 0.05 were considered significant.
Results
During the study period, Bronchiolitis was the most common cause of ICU admission, and was responsible for 9,628 (27.6%) of 34,829 non-elective admissions in infants below two years of age. 324 infants with tracheostomies in situ at time of admission were excluded. Prematurity (20 %), chronic respiratory conditions (10%) and congenital cardiac disease (7 %) were the most common underlying conditions ( 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 5.80/100,000; 95%-CI 3.68 to 7.90), and when restricting to ICUs that had contributed to the registry for the entire study duration (6.21/100,000; 95%-CI 3.80 to 8.63). The increase in bronchiolitis admission was higher compared to admissions due to any respiratory infection, and higher compared to all annual PICU admissions, which increased from 1933 to 4115 (Table 2) .
In 2002, 37% of patients with bronchiolitis were intubated/invasively ventilated, in comparison to only 11% in 2014 (p<0.001, Figure 2 and Supplementary Table 1 ). In view of the concomitant dramatic increase in bronchiolitis-related ICU admission rates, we calculated estimates of population-based intubation rates (Supplementary Table 2 ). Absolute intubation numbers and population-based intubation rates in infants with bronchiolitis did not decrease significantly during the study period was accompanied by a reduction in the use of NIV. The findings observed in the entire cohort were confirmed in subgroup analyses restricted to PICUs only, and to PICUs and ICUs that had contributed to the registry for the entire study duration (Figure 2 and Supplementary Table 1 and 2). In multivariate analyses, age, interhospital transport, major chronic conditions, prematurity, and severity indicators such as low systolic blood pressure were identified as significant predictors for intubation (Table 3; Table 3A ). For children treated with HFNC, younger age, bronchopulmonary dysplasia, congenital heart defects, low blood pressure, and increased negative base excess were the main predictors of intubation (p<0.01, Supplementary Table 3B) .
When comparing the risk-adjusted rate of an infant with bronchiolitis receiving invasive ventilation, important differences between units were noted (Figure 4) . When compared to an intercept-only mixed effects model, a model which controlled for year and patient risk factors (Table 3 ) demonstrated a 39.1% reduction in the variance of the random effect. This suggests that 60.9% of the variation in intubation rates were not explained by the case mix nor by time trends, and likely reflect underlying differences in unit-to-unit practice. Using the average risk profile for intubation, the probability a child with bronchiolitis being intubated varied from 6.9% to 36.7% across units.
We assessed total direct hospitalization-related costs in infants requiring ICU admission, including ICU and ward costs. However, the findings were reproduced in subgroup analyses restricted to PICUs, and restricted to those centers that had provided data for the entire study duration.
Infants with bronchiolitis admitted in recent years to ICU were less likely to have underlying comorbidities, older, and their predicted mortality was lower, suggesting changing thresholds for ICU admission. At the same time, we observed a considerable variability in practice between units, with over six-fold differences in Of note, the study period witnessed the implementation of rapid response teams and early warning tools (EWTs) in the major pediatric hospitals, followed by regional hospitals. While EWTs have been shown to predict the need for ICU admission, and reduce cardiopulmonary arrests in ward setting [16] , to the best of our knowledge they have not been validated specifically for bronchiolitis. Indeed, infants with severe bronchiolitis commonly manifest tachycardia, tachypnea, and increased work of breathing, and may relatively rapidly trigger EWTs -with an unknown impact on health outcomes and resource utilization.
Our data shows that this increase in ICU admission rates has been associated with a rapid expansion in costs, despite a reduction in LOS in intensive care and a shorter duration of ventilation. Our costs are comparable to a recent European study, which reported a four times higher cost for children requiring ICU compared to those treated on the ward (EUR €8061 versus €1834)[17].
Our study demonstrates that despite lack of larger trials on HFNC use in infants, HFNC therapy has become the most common support mode for critically ill infants with bronchiolitis in Australia and New Zealand recently, with over 70% of admissions in 2014 supported with HFNC. At the same time, while the proportion of admissions requiring intubation and IV dropped, we did not observe a significant reduction in the absolute number of children requiring IV. Our observation parallels several single center studies reporting a drop in intubation rates in patients with severe bronchiolitis following the increased use of NIV and HFNC [10, 12, 13, [18] [19] [20] [21] [22] , and suggests that these have led to a major change of practice in the absence of higher grade evidence. Recent large randomized trials in adults have demonstrated efficacy of HFNC therapy for acute hypoxemic respiratory failure [23, 24] . In the neonatal population, HFNC therapy was shown to be non-inferior to nasal CPAP [25, 26] .
While the physiological effects of HFNC therapy, including provision of 4-5cm H 2 O CPAP, reduction in inspiratory work of breathing through provision of flows matching or greater than peak inspiratory flows, and washout of nasopharyngeal deadspace have been independently confirmed [27, 28] , there is a lack of randomized-controlled trials to support either outcome benefit or cost benefit of HFNC therapy in the pediatric age group. A recent adult single center study has reported higher mortality in patients treated with HFNC that required delayed emergency intubation [29] . In our cohort, the increasing use of HFNC was not associated with a delay in intubations, and in fact the proportion of late intubations, mortality, length of mechanical ventilation, and length of ICU stay decreased.
Advantages of HFNC therapy include an excellent safety profile, low equipment costs, easy application, and increased patient comfort compared to other forms of respiratory support. As a result, the application of HFNC therapy outside ICU settings has been increasingly tested, and single centre studies suggest safety, feasibility, and efficiency of such an approach [18] , although the translation of this approach into better outcomes remains to be proven. Bronchiolitis is a relatively uniform disease with close to zero mortality, patients mostly demonstrate gradual rather than precipitous deterioration, and predictors can be used to stratify severity [30] . As a 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 respiratory support mode prior to 2010. Furthermore, we did not have access to detailed microbiological data, and extended nasopharyngeal virus polymerase-chain reaction tests were not consistently performed in centers throughout the study.
Because the large majority of infants with bronchiolitis admitted to ICU did not receive intra-arterial monitoring on admission, we were unable to stratify by the degree of hypoxemia. Finally, FiO 2 /SpO 2 ratios could not be used as the true FiO 2 is unknown in HFNC or low flow oxygen therapy. In addition, we did not have access to pCO 2 values measured on admission to ICU, however elevated pCO 2 represent a common finding in bronchiolitis and may not indicate necessarily a need for intubation [34] .
In conclusion, severe bronchiolitis remains responsible for a huge burden of disease.
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nz/estimates-projections).
The diagnosis of bronchiolitis was based on the prospective diagnostic coding used in each patient in the ANZPIC Registry, including the principal diagnosis, the underlying diagnosis, or any of the associated diagnoses. The coding is based on the ICU discharge diagnosis by the ICU physicians.
Comorbidity definitions:
The following comorbidities were defined to characterize patients with underlying disease: prematurity (< 37 weeks gestational age), chronic lung disease, underlying chronic respiratory disease other than prematurity-related chronic lung disease, congenital heart disease, chronic neurologic disease (encephalopathy; chronic central or peripheral nervous system disease), and other comorbidities (including renal disease, immunodeficiency or immunosuppression, haematological or solid organ tumors, status post bone marrow transplantation, and solid organ transplant recipients).
Cost estimates:
The ANZPIC registry data were used to estimate the costs of bronchiolitis in Australia and New Zealand, using 2014 Australian dollar costings. The costing model applied standardised prices from the National Efficient Price Determination (2014/2015) (https://www.ihpa.gov.au/sites/g/files/net636/f/publications/national_efficient_price_determination_2014-15.pdf). This model presents the activity based funding that would be provided by the Commonwealth to hospitals, based on an assumed Australian Refined Diagnosis -Related Group of Bronchiolitis with complications (E70A), weighted for time spent in intensive care, length of hospital stay and/or paediatric service. For the years 2003-2014 if data for hospital LOS were missing, imputation was used based on the median LOS for that corresponding year for general or paediatric ICU settings. As there were limited hospital LOS data available for 2002, the median LOS for 2003 was imputed for 2002.
Statistics and risk prediction models:
To assess change in risk-adjusted mortality, we recalibrated PIM2 among these patients using the linear prediction of the PIM2 model in a logistic regression model. Populationbased admission rate estimates were calculated. We assessed linear trends in respiratory support over the 13-year period. In addition, trends during the 13-year study period were 2 assessed by comparing risk-adjusted need for invasive ventilation. We constructed a multivariate prediction model for the need for invasive ventilation. For multivariable models, all significant predictors from the univariable analyses were used. We used a backward stepwise elimination procedure to eliminate non-significant predictors based on p>0.05. For risk prediction models, we ran a saturated mix-effects logistic regression model clustering on site. The variance of the random effect was used as a measure of unit-level variation. To avoid spurious associations between predictors that were correlated with time, we ran the saturated model with the year of admission. The model building process was undertaken using backward elimination of the covariate with the highest p-value. We selected the final model based on the lowest Akaike information criterion (AIC)
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